A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells

FEMS Immunology and Medical Microbiology

Volumn 51, Issue 1, 2007, Pages 26-34

  Cong, Zhongyi ^a   Wan, Min ^a   Wu, Xiuli ^a   Wang, Li ^a   Hu, Xiaoping ^a   Yang, Fenglei ^a   Bao, Musheng ^a   Zhang, Xuesong ^b   Chen, Jianzhu ^c   Wang, Liying ^a   Yu, Yongli ^a  

^a JILIN UNIVERSITY   (China)

^b Blood Center of Jilin Province   (China)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Coxsackie virus; CpG ODN; IFN ; IFN ; IFN ; IFN

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; MESSENGER RNA;

ARTICLE; COXSACKIE VIRUS B3; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIVIRAL AGENTS; CELL LINE; ENTEROVIRUS B, HUMAN; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; OLIGODEOXYRIBONUCLEOTIDES;

EID: 34548585992     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00266.x     Document Type: Article

References (50)

1. Ashkar AA, Bauer S, Mitchell WJ, Vieira J Rosenthal KL (2003) Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol 77 : 8948 8956.
2. Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, Pohl D, Freedman M, Schelensky L Antonijevic I (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66 : 472 476.
3. Bao M, Zhang Y, Wan M et al 2006) Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin Immunol 118 : 180 187.
4. Barnes BJ, Moore PA Pitha PM (2001) Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 276 : 23382 23390.
5. Bolanaki E, Kottaridi C, Markoulatos P, Margaritis L Katsorchis T (2005) A comparative amplification of five different genomic regions on Coxsackie A and B viruses. Implications in clinical diagnostics. Mol Cell Probes 19 : 127 135.
6. Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ Jr., MacGowan GA, Murali S, Rosenblum WD, Feldman AM McNamara DM (1999) Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34 : 177 180.
7. Braiteh F, Boxrud C, Esmaeli B Kurzrock R (2005) Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 106 : 2992 2994.
8. Cajean-Feroldi C, Nosal F, Nardeux PC, Gallet X, Guymarho J, Baychelier F, Sempe P, Tovey MG, Escary JL Eid P (2004) Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity. Biochemistry 43 : 12498 12512.
9. Dahl H, Linde A Strannegard O (2004) In vitro inhibition of SARS virus replication by human interferons. Scand J Infect Dis 36 : 829 831.
10. Derwenskus J Lublin FD (2006) Use of interferon-beta in the treatment of multiple sclerosis. Adv Neurol 98 : 257 271.
11. Dong L, Mori I, Hossain MJ, Liu B Kimura Y (2003) An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J Gen Virol 84 : 1623 1628.
12. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M Jacobs S (2000) Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68 : 556 567.
13. Gurney KB, Colantonio AD, Blom B, Spits H Uittenbogaart CH (2004) Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection. J Immunol 173 : 7269 7276.
14. Harandi AM, Eriksson K Holmgren J (2003) A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 77 : 953 962.
15. Heim A, Brehm C, Stille-Siegener M, Muller G, Hake S, Kandolf R Figulla HR (1995) Cultured human myocardial fibroblasts of pediatric origin: natural human interferon-alpha is more effective than recombinant interferon-alpha 2a in carrier-state coxsackievirus B3 replication. J Mol Cell Cardiol 27 : 2199 2208.
16. Heim A, Grumbach I, Pring-Akerblom P, Stille-Siegener M, Muller G, Kandolf R Figulla HR (1997) Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha. Antiviral Res 34 : 101 111.
17. Hyypia T Stanway G (1993) Biology of coxsackie A viruses. Adv Virus Res 42 : 343 373.
18. Kishimoto C, Crumpacker CS Abelmann WH (1988) Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 12 : 1334 1341.
19. Koyama T, Sakamoto N, Tanabe Y et al 2005) Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol Res 34 : 41 49.
20. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM Hartmann G (2001) Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31 : 2154 2163.
21. Kurokohchi K, Takaguchi K, Kita K, Masaki T Kuriyama S (2005) Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. World J Gastroenterol 11 : 5401 5403.
22. Levi D Alejos J (2001) Diagnosis and treatment of pediatric viral myocarditis. Curr Opin Cardiol 16 : 77 83.
23. Li N, Fan XG, Chen ZH, Zhu C, Liu HB Huang Y (2006) Inhibition of the hepatitis B virus replication in vitro by an oligodeoxynucleotide containing cytidine-guanosine motifs. Immunol Lett 102 : 60 66.
24. Liu PP Mason JW (2001) Advances in the understanding of myocarditis. Circulation 104 : 1076 1082.
25. Lok AS, Lai CL Leung EK (1990) Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 12 : 1266 1270.
26. Maeda S, McCandliss R, Gross M, Sloma A, Familletti PC, Tabor JM, Evinger M, Levy WP Pestka S (1980) Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon. Proc Natl Acad Sci USA 77 : 7010 7013.
27. Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL Van Nest G (2003) Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 73 : 781 792.
28. McNamara DM, Rosenblum WD, Janosko KM, Trost MK, Villaneuva FS, Demetris AJ, Murali S Feldman AM (1997) Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 95 : 2476 2478.
29. Nyman TA, Tolo H, Parkkinen J Kalkkinen N (1998) Identification of nine interferon-alpha subtypes produced by Sendai virus-induced human peripheral blood leucocytes. Biochem J 329 : 295 302.
30. Oberg K Alm GV (1989) Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. J Interferon Res 9 (Suppl 1), S45 S49.
31. Olbrich AR, Schimmer S, Heeg K, Schepers K, Schumacher TN Dittmer U (2002) Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol 76 : 11397 11404.
32. Olbrich AR, Schimmer S Dittmer U (2003) Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J Virol 77 : 10658 10662.
33. Patel DD, Kapoor A, Ayyagari A Dhole TN (2004) Development of a simple restriction fragment length polymorphism assay for subtyping of coxsackie B viruses. J Virol Methods 120 : 167 172.
34. Pestka S (2000) The human interferon alpha species and receptors. Biopolymers 55 : 254 287.
35. Pestka S, Langer JA, Zoon KC Samuel CE (1987) Interferons and their actions. Annu Rev Biochem 56 : 727 777.
36. Pestka S, Krause CD Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202 : 8 32.
37. Pulli T, Koskimies P Hyypia T (1995) Molecular comparison of coxsackie A virus serotypes. Virology 212 : 30 38.
38. Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, Brown C, Van Nest G Stanberry LR (2002) Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 76 : 11387 11396.
39. Rezkalla SH, Raikar S Kloner RA (1996) Treatment of viral myocarditis with focus on captopril. Am J Cardiol 77 : 634 637.
40. Sambrook J Russell DW (2001) Purification of RNA from cells and tissues by acid phenol-guanidinium thiocyanate-chloroform extraction. Molecular Cloning: A Laboratory Manual, 3rd edn. pp. 7.4 7.8. Cold Spring Harbor Laboratory, New York, NY.
41. Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14 : 778 809.
42. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45 : 932 943.
43. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P Sharma BC (2005) Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 100 : 2463 2471.
44. Schanen C, Chieux V, Lobert PE, Harvey J Hober D (2006) Correlation between the anti-virus-induced cytopathic effect activity of interferon-alpha subtypes and induction of MxA protein in vitro. Microbiol Immunol 50 : 19 24.
45. Schlaepfer E, Audige A, von Beust B, Manolova V, Weber M, Joller H, Bachmann MF, Kundig TM Speck RF (2004) CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol 78 : 12344 12354.
46. See DM Tilles JG (1992) Treatment of Coxsackievirus A9 myocarditis in mice with WIN 54954. Antimicrob Agents Chemother 36 : 425 428.
47. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S Liu YJ (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284 : 1835 1837.
48. Tokunaga T, Yano O, Kuramoto E, Kimura Y, Yamamoto T, Kataoka T Yamamoto S (1992) Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol 36 : 55 66.
49. Ward RP Kugelmas M (2005) Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician 72 : 655 662.
50. Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R Agrawal S (2002) Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun 297 : 83 90.